Could $120m Make Editas 1st in Clinic With CRISPR?
This article was originally published in Scrip
No company working with the genome-editing technology known as CRISPR has taken a therapeutic candidate into the clinic, but Editas Medicine has raised $120m in Series B private financing to refine its platform and prepare its first potential products for human testing.
You may also be interested in...
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.